美国食品和药物管理局批准高剂量Wegovy (7.2毫克) 用于需要更多减肥的成年人,试验显示平均体重减少19%. The FDA approved a higher-dose Wegovy (7.2 mg) for obese adults who need more weight loss, showing 19% average weight reduction in trials.

美国食品和药物管理局已批准高剂量版本的Wegovy (7. 2 mg),现在可在4月份使用,适用于耐受2. 4mg剂量的肥胖成年人并需要进一步减轻体重. The FDA has approved a higher-dose version of Wegovy (7.2 mg), now available in April, for adults with obesity who’ve tolerated the 2.4 mg dose and need further weight loss. 临床试验显示,高剂量导致17个月的平均体重减轻19%,而低剂量则为16%. 其中31%的人至少减少了25%. Clinical trials showed the higher dose led to an average 19% body weight loss over 17 months, compared to 16% on the lower dose, with 31% achieving at least 25% weight loss. 药物与饮食和运动一起使用,副作用包括恶心,吐,便秘以及皮肤灼热感更频繁. The drug is used with diet and exercise, and side effects including nausea, vomiting, constipation, and a burning skin sensation occurred more frequently. 报告的严重不良反应发生在近7% 的使用者中. Serious adverse events were reported in nearly 7% of users. 欧洲监管机构在2月份已经批准了更高剂量. European regulators had already approved the higher dose in February. 价格细节尚未公布. Pricing details are pending.